Daewoong Pharmaceutical Obtains Singapore Product Approval for Botulinum Toxin 'Nabota'

First Domestic Botulinum Toxin Obtains Approval in Singapore

[Asia Economy Reporter Myunghwan Lee] Daewoong Pharmaceutical announced on the 9th that its botulinum toxin 'Nabota' obtained product approval in Singapore on the 20th of last month. Nabota is the first domestically produced botulinum toxin to be approved in Singapore.

The product approved by the Singapore Health Sciences Authority is Nabota 100 units. Daewoong Pharmaceutical obtained the approval after about 1 year and 5 months since applying for product approval in September 2021.

Daewoong Pharmaceutical plans to launch Nabota in Singapore in the third quarter. Hyphens Pharma, a subsidiary of Hyphens Group listed on the Singapore Exchange (SGX), will be responsible for local distribution and sales.

Although the botulinum toxin market in Singapore is smaller compared to other Southeast Asian countries, the beauty and medical industries have developed due to the high national income. Therefore, Singapore is considered a strategic hub for expanding the regional market, and Daewoong Pharmaceutical expects gradual expansion to neighboring countries and increased brand awareness.

Seongsu Park, Vice President of Daewoong Pharmaceutical, said, "Singapore is a country with significant influence on the Asian beauty and medical industries. It is meaningful that we obtained approval in Singapore as the first domestic botulinum toxin brand, and we expect this to accelerate the expansion of Nabota's market share in the Asian region."

Nabota is a botulinum toxin product launched domestically by Daewoong Pharmaceutical in 2014, and it is the only botulinum toxin in Asia that has received approval from the U.S. Food and Drug Administration (FDA), as well as in Korea.

This content was produced with the assistance of AI translation services.